NAWALOKA HOSPITALS PLC Financial Summary
NHL.N0000 · NAWALOKA HOSPITALS PLC · Health Care Equipment & Services · 2026-09-01
Nawaloka Hospitals PLC Financial Summary and Investment Analysis
Executive Overview
Nawaloka Hospitals PLC is a premier private multi-specialist healthcare provider in Sri Lanka, operating a flagship hospital, a nationwide laboratory and pharmacy network, and specialized healthcare centers. Over the analyzed periods, the company achieved a significant financial and operational turnaround. A landmark debt restructuring effort—refinancing its Hatton National Bank facility with the Bank of Ceylon—substantially reduced finance costs and eased capital constraints. Concurrently, the company positioned itself as a technological pioneer in the region, launching South Asia's first AI-powered radiology suite and a proprietary digital patient portal (AI-DOC).
The reports indicate robust revenue growth driven by increased insurance-funded admissions, medical tourism, and high-acuity specialized care. While the company achieved record net profits in the 12 months ending Q1 2026, working capital deficits and ongoing litigation pose persistent, manageable risks.
Key periods covered: Q4 2023 to Q2 2026.
Financial Performance
Revenue and Profitability Trends
| Period | Revenue (Rs. '000) | Gross Profit (Rs. '000) | Net Profit/Loss (Rs. '000) | GP Margin | NP Margin |
|---|---|---|---|---|---|
| 12 Months Ended Q1 2025 | 11,012,689 | 5,691,902 | 56,381 | 51.68% | 0.51% |
| 12 Months Ended Q1 2026 | 13,242,883 | 7,331,544 | 1,054,432 | 55.36% | 7.96% |
| Q3 2025 | 3,536,949 | 1,980,106 | 294,240 | 55.98% | 8.32% |
| Q4 2025 | 3,438,428 | 1,959,873 | 139,647 | 57.00% | 4.06% |
| Q1 2026 | 3,046,447 | 1,695,100 | 142,912 | 55.64% | 4.69% |
| Q2 2026 | 3,534,582 | 1,994,383 | 71,064 | 56.42% | 2.01% |
Analysis:
- Revenue Growth: Revenue grew by ~20.2% YoY for the 12 months ended Q1 2026. This was fueled by a diversified payer mix (insurance-funded admissions reached 35%), medical tourism, and higher-acuity clinical services (e.g., interventional cardiology).
- Profitability Turnaround: The company transitioned from a marginal net profit in the 12 months ending Q1 2025 to a record high of Rs. 1.05 Billion in the 12 months ending Q1 2026. This massive surge was significantly aided by operational efficiencies, cost controls, and a substantial one-off gain on loan settlement amounting to Rs. 660.76 Million realized during Q2/Q3 2025.
- Recent Quarters: Q2 2026 revenue was strong, though net profit margins normalized to 2.01%, reflecting standard operational baselines absent major one-off restructuring gains.
Balance Sheet Analysis
| As at Period End | Total Assets (Rs. '000) | Total Liabilities (Rs. '000) | Total Equity (Rs. '000) | Current Ratio | Debt/Equity Ratio |
|---|---|---|---|---|---|
| Q1 2025 | 20,023,511 | 15,110,648 | 4,912,863 | 0.32 | 1.36 |
| Q3 2025 | 21,258,034 | 15,316,192 | 5,941,843 | 0.75 | 1.41 |
| Q4 2025 | 21,593,341 | 15,511,851 | 6,081,490 | 0.70 | 1.25 |
| Q1 2026 | 22,754,511 | 16,279,450 | 6,475,061 | 0.62 | 1.12 |
| Q2 2026 | 22,041,701 | 15,977,273 | 6,064,428 | 0.68 | 1.32 |
Analysis:
- Liquidity: The company operates with a persistent working capital deficit, reflected in a current ratio remaining below 1.0x (0.68 in Q2 2026). Management mitigates this via secured overdraft facilities, improved collections, and disciplined expenditure tracking.
- Solvency & Debt Profile: The strategic debt restructuring replaced the Hatton National Bank facility with a Bank of Ceylon facility at lower interest rates. The Debt-to-Equity ratio has improved to more sustainable levels (~1.12 to 1.32 range), driven by higher retained earnings.
Cash Flow Analysis
| Cash Flow Component | 12 Months Ended Q1 2026 (Rs. '000) | 12 Months Ended Q1 2025 (Rs. '000) |
|---|---|---|
| Operating | 769,853 | 1,133,437 |
| Investing | (2,095,268) | (407,013) |
| Financing | 1,509,507 | (757,251) |
| Net Change | 184,092 | (30,826) |
Analysis:
- Operating Cash Flow: Remained positive but decreased YoY due to higher interest/tax payouts and working capital absorptions linked to revenue scaling.
- Investing Cash Flow: A massive spike in CapEx (Rs. 2.19 Billion) was recorded in the 12 months ending Q1 2026, primarily allocated to the new AI-powered radiology suite, medical equipment, and digital infrastructure.
- Financing Cash Flow: Reflects the major debt restructuring, involving Rs. 7.69 Billion in new loan proceeds and Rs. 6.10 Billion in loan repayments. No dividends were paid out during these periods.
Key Financial Ratios and Growth Indicators
- Profitability: Return on Equity (ROE) surged to 16.28% in the 12 months ended Q1 2026 from 1.15% the prior year. Return on Assets (ROA) improved to 7.62% from 5.04%.
- Valuation & EPS: EPS stood at Rs. 0.75 for the 12 months ended Q1 2026, compared to Rs. 0.04 in the prior year. Net Asset Value (NAV) per share was Rs. 4.30 as of Q2 2026.
- Growth & Service Metrics: Achieved >95% laboratory turnaround time success, a patient satisfaction score of 4.8/5, and handled approximately 38,000 channeling appointments monthly.
Economic and Market Context
The Sri Lankan economy's gradual recovery from the 2022 macroeconomic crisis has stabilized the operating environment. However, the company faces headwinds from healthcare inflation—specifically, the rising costs of imported pharmaceuticals, medical devices, and high utility tariffs. Demographic shifts, notably an aging population and a rise in non-communicable diseases (NCDs), are structurally driving demand for advanced diagnostics, oncology, cardiology, and preventive healthcare. The company is actively capitalizing on regional medical tourism, drawing patients from the Maldives, Bangladesh, and the Middle East to hedge against local economic fluctuations.
Future Potential and Outlook
- Technological Leadership: Positioning as Sri Lanka’s first AI-enabled hospital. Expansion of the proprietary "AI-DOC" patient portal, digital records, and active evaluation of robotic-assisted surgery.
- Facility Expansions: Upcoming projects include a dedicated Eye Theatre, a Comprehensive Orthopedic Centre, and upgraded Mother & Baby Care units.
- Medical Tourism: The company is uniquely integrated into national medical tourism policy drafts, targeting significant foreign currency revenue growth.
Risks and Challenges
- Legal/Contingencies: A high-profile legal dispute exists regarding the cancellation of 5,049,500 shares of Nawaloka College of Higher Studies (Private) Limited. A December 2024 court ruling favored the petitioner, directing the company to alter its share registry and pay Rs. 78 Million plus interest. The company appealed this in January 2025 and currently maintains no provision for the loss, citing confidence in its legal standing.
- Operational Risk: Intense competition for skilled healthcare professionals and "brain drain" (migration of medical staff) threaten service continuity. This is actively mitigated by the in-house Nursing Training School, a Caregiver Academy, and competitive remuneration.
- Working Capital: A negative net current asset position requires tight day-to-day liquidity management.
Shareholder and Corporate Information
- Major Shareholders: Mr. H K J Dharmadasa (Chairman/CEO) holds ~32.83%, and Nawaloka Construction Company (Private) Limited holds ~31.34%.
- Public Holding: Represents 34.28% (483,248,140 shares) distributed among 8,379 shareholders as of Q2 2026.
- Market Performance: The stock demonstrated strong momentum, climbing from Rs. 5.30 to Rs. 10.60 (+100%) during the 12 months ending Q1 2026. Recent trading data reflects a closing price of Rs. 12.90. Float-adjusted market capitalization reached ~Rs. 7.05 Billion by Q2 2026.
- Dividend History: No dividends were declared or paid in the trailing periods to conserve cash for debt reduction and CapEx.
Investment Decision Indicators
Strengths:
- Exceptional Turnaround: Successful loan restructuring drastically lowered finance costs and averted liquidity crises.
- Tech & Infrastructure Moat: Heavy investments in AI diagnostics and premium facilities create high barriers to entry and strong pricing power.
- Diversified Revenue: Growing footprints in lucrative medical tourism and corporate insurance segments.
Weaknesses:
- Liquidity Strain: The current ratio consistently below 1.0 indicates a vulnerability to short-term cash flow shocks.
- Litigation Overhang: The adverse ruling on the associate company shares (currently under appeal) risks a sudden Rs. 78M+ liability and loss of the asset.
Opportunities and Threats:
- *Opportunities:* Sri Lanka's demographic transition to an aging population guarantees long-term volume growth.
- *Threats:* Global brain drain depleting specialist local talent; utility/inflationary pressures shrinking gross margins if costs cannot be fully passed to patients.
Overall Assessment: The company presents a profile of an aggressive, technology-forward healthcare leader emerging successfully from a period of heavy financial distress. The recent surge in net profitability highlights the efficacy of its debt restructuring and operational streamlining. Investors heavily weighting long-term capital growth and market dominance in specialized care will find the underlying operational metrics highly attractive. However, due to the persistent negative working capital position, lack of dividend payouts, and looming litigation risks, the stock requires a tolerance for short-term liquidity and legal uncertainties.